AMP-activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Biochem Biophys Res Commun. 2010 Jan 1;391(1):147-51. doi: 10.1016/j.bbrc.2009.11.022. Epub 2009 Nov 10.

Abstract

The selective loss of dopaminergic neurons in the substantia nigra pars compacta is a feature of Parkinson's disease (PD). 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity is the most common experimental model used to investigate the pathogenesis of PD. Administration of MPTP in mice produces neuropathological defects as observed in PD and 1-methyl-4-pyridinium (MPP(+)) induces cell death when neuronal cell cultures are used. AMP-activated protein kinase (AMPK) is a key regulator of energy homeostasis. In the present study, we demonstrated that AMPK is activated by MPTP in mice and MPP(+) in SH-SY5Y cells. The inhibition of AMPK by compound C resulted in an increase in MPP(+)-induced cell death. We further showed that overexpression of AMPK increased cell viability after exposure to MPP(+) in SH-SY5Y cells. Based on these results, we suggest that activation of AMPK might prevent neuronal cell death and play a role as a survival factor in PD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology
  • AMP-Activated Protein Kinases / biosynthesis*
  • Animals
  • Apoptosis
  • Cell Line, Tumor
  • Dopamine Agents / pharmacology
  • Enzyme Activation
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Neurons / drug effects
  • Neurons / enzymology*
  • Parkinson Disease / enzymology*

Substances

  • Dopamine Agents
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • AMP-Activated Protein Kinases